Biotech Market Spotlight: Sonic Healthcare
Wednesday, 02 December, 2009
Pathology and health care company, Sonic Healthcare (ASX:SHL), has continued its spending spree by acquiring Rhode Island-based East Side Clinical Laboratory in the U.S. for an undisclosed sum.
This is the third lab acquired by Sonic in the past four months, and it's expected the company may purchase more labs in the U.S. and Germany.
East Side was established in 1949 and has developed in to a leading provider of clinical and laboratory services in the state of Rhode Island.
According to Sonic, Ease Side has annual revenues of over US$30 million.
At Sonic's AGM, held mid-November, management re-affirmed its expectation to see 10-15% growth in net profit for FY2010, provisional on currency fluctuations.
In today's trading, Sonic has gained 44c, or 3.1%, to $14.46.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
